Statkraft AS
S&P downgrades Statkraft’s credit rating from A to A-, in line with the company’s long-standing rating target
S&P downgrades Statkraft’s credit rating from A to A-, in line with the company’s long-standing rating target
Today S&P announced a one notch downgrade of Statkraft AS citing weakening performance and financial metrics. The long-term issuer credit rating was lowered from A to A- with a stable outlook.
The rating change aligns with the company’s long-standing rating targets. Statkraft has consistently maintained a target of an A- rating from S&P and a BBB+ from Fitch. Statkraft remains committed to maintaining these targets.
On 18 June, Statkraft announced a new and refocused strategy, strengthening core activities and competitiveness:
https://www.statkraft.com/newsroom/news-and-stories/2025/statkraft-strengthens-core-activities-and-competitiveness-following-strategic-review/
For the latest updates on strategy execution, please refer to the Q3 2025 presentation: https://www.statkraft.com/globalassets/0/.com/6-investor-relations/reports-and-presentations/2025/q3/presentation---statkraft-as---q3-2025.pdf
The rating report is available on Statkraft’s website:
https://www.statkraft.com/IR/funding-and-credit-rating/
For further information, please contact:
Funding Manager André Halle Julin, tel.: +47 992 54 205
VP Group Treasury Stephan Skaane, tel.: +47 905 13 652
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SBM Offshore Amsterdam B.V.12.11.2025 18:13:35 CET | Press release
SBM Offshore announces proposed CEO and Supervisory Board reappointments
BetaGlue Therapeutics SpA12.11.2025 18:00:00 CET | Press release
MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
Verkkokauppa.com Oyj12.11.2025 18:00:00 CET | Press release
Verkkokauppa.com Oyj: Acquisition of own shares on 12 November 2025
LECTRA12.11.2025 17:58:51 CET | Press release
Lectra: Monthly declaration of the total number of shares and voting rights composing the company's capital (at October 31st, 2025)
Solvay S.A.12.11.2025 17:45:00 CET | Press release
Participation notifications by Morgan Stanley
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom